About Cytochroma Inc.:

Cytochroma Inc. is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD).  The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Cytochroma has three lead product candidates in development for CKD patients—CTA018 Injection and CTAP201 Injection for the treatment of SHPT and CTAP101 Capsules for the treatment of vitamin D insufficiency.  The Company’s lead products address a significant need for new therapeutic options to better control these disorders and their associated morbidities such as endocrine, cardiovascular, and bone and mineral diseases.  Cytochroma’s vitamin-D based therapeutics address target markets projected to reach more than $1.4 billion annually by 2013 in the U.S.

Cytochroma’s expertise in vitamin D chemistry, biochemistry, metabolism and physiology, combined with its experience in bringing vitamin D-based therapeutics to market uniquely positions the Company to improve the lives of CKD patients suffering from diseases related to vitamin D insufficiency and SHPT.